These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 21126792)

  • 1. Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease.
    Zein CO; Unalp A; Colvin R; Liu YC; McCullough AJ;
    J Hepatol; 2011 Apr; 54(4):753-9. PubMed ID: 21126792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients.
    Ong JP; Elariny H; Collantes R; Younoszai A; Chandhoke V; Reines HD; Goodman Z; Younossi ZM
    Obes Surg; 2005 Mar; 15(3):310-5. PubMed ID: 15826462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Smoking is associated with severity of liver fibrosis but not with histological severity in nonalcoholic fatty liver disease. Results from a cross-sectional study.
    Munsterman ID; Smits MM; Andriessen R; van Nieuwkerk CMJ; Bloemena E; Mulder CJJ; Tjwa ETTL; van Geenen EJM
    Scand J Gastroenterol; 2017 Aug; 52(8):881-885. PubMed ID: 28446050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ultrasonographic Nonalcoholic Fatty Pancreas Is Associated with Advanced Fibrosis in NAFLD: A Retrospective Analysis.
    Rosenblatt R; Mehta A; Snell D; Hissong E; Kierans AS; Kumar S
    Dig Dis Sci; 2019 Jan; 64(1):262-268. PubMed ID: 30269271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C-peptide is associated with NAFLD inflammatory and fibrotic progression in type 2 diabetes.
    Wang N; Wang Y; Zhang W; Chen Y; Chen X; Wang C; Li Q; Chen C; Jiang B; Lu Y
    Diabetes Metab Res Rev; 2020 Feb; 36(2):e3210. PubMed ID: 31351021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progression of Nonalcoholic Fatty Liver Disease-Associated Fibrosis in a Large Cohort of Patients with Type 2 Diabetes.
    Noureddin N; Noureddin M; Singh A; Alkhouri N
    Dig Dis Sci; 2022 Apr; 67(4):1379-1388. PubMed ID: 33779880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease.
    Kleiner DE; Brunt EM; Wilson LA; Behling C; Guy C; Contos M; Cummings O; Yeh M; Gill R; Chalasani N; Neuschwander-Tetri BA; Diehl AM; Dasarathy S; Terrault N; Kowdley K; Loomba R; Belt P; Tonascia J; Lavine JE; Sanyal AJ;
    JAMA Netw Open; 2019 Oct; 2(10):e1912565. PubMed ID: 31584681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients.
    Nakahara T; Hyogo H; Yoneda M; Sumida Y; Eguchi Y; Fujii H; Ono M; Kawaguchi T; Imajo K; Aikata H; Tanaka S; Kanemasa K; Fujimoto K; Anzai K; Saibara T; Sata M; Nakajima A; Itoh Y; Chayama K; Okanoue T;
    J Gastroenterol; 2014 Nov; 49(11):1477-84. PubMed ID: 24277052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients.
    Treeprasertsuk S; Björnsson E; Enders F; Suwanwalaikorn S; Lindor KD
    World J Gastroenterol; 2013 Feb; 19(8):1219-29. PubMed ID: 23482703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors.
    Leite NC; Villela-Nogueira CA; Pannain VL; Bottino AC; Rezende GF; Cardoso CR; Salles GF
    Liver Int; 2011 May; 31(5):700-6. PubMed ID: 21457442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; McNeil R; Turner MJ; Han B; Provenzale D; Choi SS; Moylan CA; Hunt CM
    Aliment Pharmacol Ther; 2018 Jan; 47(2):268-278. PubMed ID: 29115682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
    Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
    Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study.
    Bhala N; Angulo P; van der Poorten D; Lee E; Hui JM; Saracco G; Adams LA; Charatcharoenwitthaya P; Topping JH; Bugianesi E; Day CP; George J
    Hepatology; 2011 Oct; 54(4):1208-16. PubMed ID: 21688282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accuracy of Noninvasive Fibrosis Scores to Detect Advanced Fibrosis in Patients With Type-2 Diabetes With Biopsy-proven Nonalcoholic Fatty Liver Disease.
    Singh A; Gosai F; Siddiqui MT; Gupta M; Lopez R; Lawitz E; Poordad F; Carey W; McCullough A; Alkhouri N
    J Clin Gastroenterol; 2020; 54(10):891-897. PubMed ID: 32168133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis.
    Loomba R; Abraham M; Unalp A; Wilson L; Lavine J; Doo E; Bass NM;
    Hepatology; 2012 Sep; 56(3):943-51. PubMed ID: 22505194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ethnicity and nonalcoholic fatty liver disease.
    Bambha K; Belt P; Abraham M; Wilson LA; Pabst M; Ferrell L; Unalp-Arida A; Bass N;
    Hepatology; 2012 Mar; 55(3):769-80. PubMed ID: 21987488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and Validation of the Nonalcoholic Fatty Liver Disease Familial Risk Score to Detect Advanced Fibrosis: A Prospective, Multicenter Study.
    Huang DQ; Ahlholm N; Luukkonen PK; Porthan K; Amangurbanova M; Madamba E; Bettencourt R; Siddiqi H; Cervantes V; Hernandez C; Lopez SJ; Richards L; Nemes K; Isoniemi H; Yki-Järvinen H; Loomba R
    Clin Gastroenterol Hepatol; 2024 Jan; 22(1):81-90.e4. PubMed ID: 37406954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycemic variability is an independent predictive factor for development of hepatic fibrosis in nonalcoholic fatty liver disease.
    Hashiba M; Ono M; Hyogo H; Ikeda Y; Masuda K; Yoshioka R; Ishikawa Y; Nagata Y; Munekage K; Ochi T; Hirose A; Nozaki-Fujimura Y; Noguchi S; Okamoto N; Chayama K; Suganuma N; Saibara T
    PLoS One; 2013; 8(11):e76161. PubMed ID: 24223115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease.
    Neuschwander-Tetri BA; Clark JM; Bass NM; Van Natta ML; Unalp-Arida A; Tonascia J; Zein CO; Brunt EM; Kleiner DE; McCullough AJ; Sanyal AJ; Diehl AM; Lavine JE; Chalasani N; Kowdley KV;
    Hepatology; 2010 Sep; 52(3):913-24. PubMed ID: 20648476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD.
    Bazick J; Donithan M; Neuschwander-Tetri BA; Kleiner D; Brunt EM; Wilson L; Doo E; Lavine J; Tonascia J; Loomba R
    Diabetes Care; 2015 Jul; 38(7):1347-55. PubMed ID: 25887357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.